Last reviewed · How we verify
Epstein-Barr Virus Specific T-Lymphocytes — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Epstein-Barr Virus Specific T-Lymphocytes (Epstein-Barr Virus Specific T-Lymphocytes) — Jessie L. Alexander.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epstein-Barr Virus Specific T-Lymphocytes TARGET | Epstein-Barr Virus Specific T-Lymphocytes | Jessie L. Alexander | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epstein-Barr Virus Specific T-Lymphocytes CI watch — RSS
- Epstein-Barr Virus Specific T-Lymphocytes CI watch — Atom
- Epstein-Barr Virus Specific T-Lymphocytes CI watch — JSON
- Epstein-Barr Virus Specific T-Lymphocytes alone — RSS
Cite this brief
Drug Landscape (2026). Epstein-Barr Virus Specific T-Lymphocytes — Competitive Intelligence Brief. https://druglandscape.com/ci/epstein-barr-virus-specific-t-lymphocytes. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab